Results of a randomized study of IM862 nasal solution in the treatment of AIDS-related Kaposi's sarcoma.
Identifieur interne : 000267 ( Ncbi/Merge ); précédent : 000266; suivant : 000268Results of a randomized study of IM862 nasal solution in the treatment of AIDS-related Kaposi's sarcoma.
Auteurs : A. Tulpule [États-Unis] ; D T Scadden ; B M Espina ; S. Cabriales ; W. Howard ; K. Shea ; P S GillSource :
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology [ 0732-183X ] ; 2000.
Descripteurs français
- KwdFr :
- Administration par voie nasale, Adulte, Adulte d'âge moyen, Calendrier d'administration des médicaments, Céphalée (), Dipeptides (administration et posologie), Dipeptides (effets indésirables), Dipeptides (usage thérapeutique), Facteur de croissance endothéliale vasculaire de type A, Facteurs de croissance endothéliale (antagonistes et inhibiteurs), Facteurs de croissance endothéliale vasculaire, Fatigue (), Femelle, Humains, Induction de rémission, Infections opportunistes liées au SIDA (traitement médicamenteux), Inhibiteurs de l'angiogenèse (administration et posologie), Inhibiteurs de l'angiogenèse (effets indésirables), Inhibiteurs de l'angiogenèse (usage thérapeutique), Inhibiteurs de protéase du VIH (usage thérapeutique), Isoformes de protéines (antagonistes et inhibiteurs), Lymphokines (antagonistes et inhibiteurs), Mâle, Nausée (), Numération des lymphocytes CD4, Paresthésie (), Sarcome de Kaposi (traitement médicamenteux), Tumeurs cutanées (traitement médicamenteux), Évolution de la maladie.
- MESH :
- administration et posologie : Dipeptides, Inhibiteurs de l'angiogenèse.
- antagonistes et inhibiteurs : Facteurs de croissance endothéliale, Isoformes de protéines, Lymphokines.
- effets indésirables : Dipeptides, Inhibiteurs de l'angiogenèse.
- traitement médicamenteux : Infections opportunistes liées au SIDA, Sarcome de Kaposi, Tumeurs cutanées.
- usage thérapeutique : Dipeptides, Inhibiteurs de l'angiogenèse, Inhibiteurs de protéase du VIH.
- Administration par voie nasale, Adulte, Adulte d'âge moyen, Calendrier d'administration des médicaments, Céphalée, Facteur de croissance endothéliale vasculaire de type A, Facteurs de croissance endothéliale vasculaire, Fatigue, Femelle, Humains, Induction de rémission, Mâle, Nausée, Numération des lymphocytes CD4, Paresthésie, Évolution de la maladie.
English descriptors
- KwdEn :
- AIDS-Related Opportunistic Infections (drug therapy), Administration, Intranasal, Adult, Angiogenesis Inhibitors (administration & dosage), Angiogenesis Inhibitors (adverse effects), Angiogenesis Inhibitors (therapeutic use), CD4 Lymphocyte Count, Dipeptides (administration & dosage), Dipeptides (adverse effects), Dipeptides (therapeutic use), Disease Progression, Drug Administration Schedule, Endothelial Growth Factors (antagonists & inhibitors), Fatigue (chemically induced), Female, HIV Protease Inhibitors (therapeutic use), Headache (chemically induced), Humans, Lymphokines (antagonists & inhibitors), Male, Middle Aged, Nausea (chemically induced), Paresthesia (chemically induced), Protein Isoforms (antagonists & inhibitors), Remission Induction, Sarcoma, Kaposi (drug therapy), Skin Neoplasms (drug therapy), Vascular Endothelial Growth Factor A, Vascular Endothelial Growth Factors.
- MESH :
- chemical , administration & dosage : Angiogenesis Inhibitors, Dipeptides.
- chemical , adverse effects : Angiogenesis Inhibitors, Dipeptides.
- chemical , antagonists & inhibitors : Endothelial Growth Factors, Lymphokines, Protein Isoforms.
- chemically induced : Fatigue, Headache, Nausea, Paresthesia.
- drug therapy : AIDS-Related Opportunistic Infections, Sarcoma, Kaposi, Skin Neoplasms.
- chemical , therapeutic use : Angiogenesis Inhibitors, Dipeptides, HIV Protease Inhibitors.
- Administration, Intranasal, Adult, CD4 Lymphocyte Count, Disease Progression, Drug Administration Schedule, Female, Humans, Male, Middle Aged, Remission Induction, Vascular Endothelial Growth Factor A, Vascular Endothelial Growth Factors.
Abstract
Although advances have been made in the treatment of AIDS-related Kaposi's sarcoma (AIDS-KS) with systemic chemotherapy, less toxic therapies are needed. IM862 is a naturally occurring peptide with antiangiogenic properties and was thus studied in patients with AIDS-KS.
DOI: 10.1200/JCO.2000.18.4.716
PubMed: 10673512
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 004B27
- to stream PubMed, to step Curation: 004B27
- to stream PubMed, to step Checkpoint: 004B27
Links to Exploration step
pubmed:10673512Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Results of a randomized study of IM862 nasal solution in the treatment of AIDS-related Kaposi's sarcoma.</title><author><name sortKey="Tulpule, A" sort="Tulpule, A" uniqKey="Tulpule A" first="A" last="Tulpule">A. Tulpule</name><affiliation wicri:level="2"><nlm:affiliation>Department of Medicine, Division of Hematology, Kenneth Norris Cancer Hospital and Research Institute, University of Southern California School of Medicine, Los Angeles, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Medicine, Division of Hematology, Kenneth Norris Cancer Hospital and Research Institute, University of Southern California School of Medicine, Los Angeles, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Scadden, D T" sort="Scadden, D T" uniqKey="Scadden D" first="D T" last="Scadden">D T Scadden</name></author><author><name sortKey="Espina, B M" sort="Espina, B M" uniqKey="Espina B" first="B M" last="Espina">B M Espina</name></author><author><name sortKey="Cabriales, S" sort="Cabriales, S" uniqKey="Cabriales S" first="S" last="Cabriales">S. Cabriales</name></author><author><name sortKey="Howard, W" sort="Howard, W" uniqKey="Howard W" first="W" last="Howard">W. Howard</name></author><author><name sortKey="Shea, K" sort="Shea, K" uniqKey="Shea K" first="K" last="Shea">K. Shea</name></author><author><name sortKey="Gill, P S" sort="Gill, P S" uniqKey="Gill P" first="P S" last="Gill">P S Gill</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2000">2000</date><idno type="RBID">pubmed:10673512</idno><idno type="pmid">10673512</idno><idno type="doi">10.1200/JCO.2000.18.4.716</idno><idno type="wicri:Area/PubMed/Corpus">004B27</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">004B27</idno><idno type="wicri:Area/PubMed/Curation">004B27</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">004B27</idno><idno type="wicri:Area/PubMed/Checkpoint">004B27</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">004B27</idno><idno type="wicri:Area/Ncbi/Merge">000267</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Results of a randomized study of IM862 nasal solution in the treatment of AIDS-related Kaposi's sarcoma.</title><author><name sortKey="Tulpule, A" sort="Tulpule, A" uniqKey="Tulpule A" first="A" last="Tulpule">A. Tulpule</name><affiliation wicri:level="2"><nlm:affiliation>Department of Medicine, Division of Hematology, Kenneth Norris Cancer Hospital and Research Institute, University of Southern California School of Medicine, Los Angeles, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Medicine, Division of Hematology, Kenneth Norris Cancer Hospital and Research Institute, University of Southern California School of Medicine, Los Angeles, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Scadden, D T" sort="Scadden, D T" uniqKey="Scadden D" first="D T" last="Scadden">D T Scadden</name></author><author><name sortKey="Espina, B M" sort="Espina, B M" uniqKey="Espina B" first="B M" last="Espina">B M Espina</name></author><author><name sortKey="Cabriales, S" sort="Cabriales, S" uniqKey="Cabriales S" first="S" last="Cabriales">S. Cabriales</name></author><author><name sortKey="Howard, W" sort="Howard, W" uniqKey="Howard W" first="W" last="Howard">W. Howard</name></author><author><name sortKey="Shea, K" sort="Shea, K" uniqKey="Shea K" first="K" last="Shea">K. Shea</name></author><author><name sortKey="Gill, P S" sort="Gill, P S" uniqKey="Gill P" first="P S" last="Gill">P S Gill</name></author></analytic><series><title level="j">Journal of clinical oncology : official journal of the American Society of Clinical Oncology</title><idno type="ISSN">0732-183X</idno><imprint><date when="2000" type="published">2000</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>AIDS-Related Opportunistic Infections (drug therapy)</term><term>Administration, Intranasal</term><term>Adult</term><term>Angiogenesis Inhibitors (administration & dosage)</term><term>Angiogenesis Inhibitors (adverse effects)</term><term>Angiogenesis Inhibitors (therapeutic use)</term><term>CD4 Lymphocyte Count</term><term>Dipeptides (administration & dosage)</term><term>Dipeptides (adverse effects)</term><term>Dipeptides (therapeutic use)</term><term>Disease Progression</term><term>Drug Administration Schedule</term><term>Endothelial Growth Factors (antagonists & inhibitors)</term><term>Fatigue (chemically induced)</term><term>Female</term><term>HIV Protease Inhibitors (therapeutic use)</term><term>Headache (chemically induced)</term><term>Humans</term><term>Lymphokines (antagonists & inhibitors)</term><term>Male</term><term>Middle Aged</term><term>Nausea (chemically induced)</term><term>Paresthesia (chemically induced)</term><term>Protein Isoforms (antagonists & inhibitors)</term><term>Remission Induction</term><term>Sarcoma, Kaposi (drug therapy)</term><term>Skin Neoplasms (drug therapy)</term><term>Vascular Endothelial Growth Factor A</term><term>Vascular Endothelial Growth Factors</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Administration par voie nasale</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Calendrier d'administration des médicaments</term><term>Céphalée ()</term><term>Dipeptides (administration et posologie)</term><term>Dipeptides (effets indésirables)</term><term>Dipeptides (usage thérapeutique)</term><term>Facteur de croissance endothéliale vasculaire de type A</term><term>Facteurs de croissance endothéliale (antagonistes et inhibiteurs)</term><term>Facteurs de croissance endothéliale vasculaire</term><term>Fatigue ()</term><term>Femelle</term><term>Humains</term><term>Induction de rémission</term><term>Infections opportunistes liées au SIDA (traitement médicamenteux)</term><term>Inhibiteurs de l'angiogenèse (administration et posologie)</term><term>Inhibiteurs de l'angiogenèse (effets indésirables)</term><term>Inhibiteurs de l'angiogenèse (usage thérapeutique)</term><term>Inhibiteurs de protéase du VIH (usage thérapeutique)</term><term>Isoformes de protéines (antagonistes et inhibiteurs)</term><term>Lymphokines (antagonistes et inhibiteurs)</term><term>Mâle</term><term>Nausée ()</term><term>Numération des lymphocytes CD4</term><term>Paresthésie ()</term><term>Sarcome de Kaposi (traitement médicamenteux)</term><term>Tumeurs cutanées (traitement médicamenteux)</term><term>Évolution de la maladie</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Angiogenesis Inhibitors</term><term>Dipeptides</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Angiogenesis Inhibitors</term><term>Dipeptides</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Endothelial Growth Factors</term><term>Lymphokines</term><term>Protein Isoforms</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Dipeptides</term><term>Inhibiteurs de l'angiogenèse</term></keywords><keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Facteurs de croissance endothéliale</term><term>Isoformes de protéines</term><term>Lymphokines</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Fatigue</term><term>Headache</term><term>Nausea</term><term>Paresthesia</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>AIDS-Related Opportunistic Infections</term><term>Sarcoma, Kaposi</term><term>Skin Neoplasms</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Dipeptides</term><term>Inhibiteurs de l'angiogenèse</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Angiogenesis Inhibitors</term><term>Dipeptides</term><term>HIV Protease Inhibitors</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections opportunistes liées au SIDA</term><term>Sarcome de Kaposi</term><term>Tumeurs cutanées</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Dipeptides</term><term>Inhibiteurs de l'angiogenèse</term><term>Inhibiteurs de protéase du VIH</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Administration, Intranasal</term><term>Adult</term><term>CD4 Lymphocyte Count</term><term>Disease Progression</term><term>Drug Administration Schedule</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Remission Induction</term><term>Vascular Endothelial Growth Factor A</term><term>Vascular Endothelial Growth Factors</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Administration par voie nasale</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Calendrier d'administration des médicaments</term><term>Céphalée</term><term>Facteur de croissance endothéliale vasculaire de type A</term><term>Facteurs de croissance endothéliale vasculaire</term><term>Fatigue</term><term>Femelle</term><term>Humains</term><term>Induction de rémission</term><term>Mâle</term><term>Nausée</term><term>Numération des lymphocytes CD4</term><term>Paresthésie</term><term>Évolution de la maladie</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Although advances have been made in the treatment of AIDS-related Kaposi's sarcoma (AIDS-KS) with systemic chemotherapy, less toxic therapies are needed. IM862 is a naturally occurring peptide with antiangiogenic properties and was thus studied in patients with AIDS-KS.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">10673512</PMID><DateCreated><Year>2000</Year><Month>07</Month><Day>13</Day></DateCreated><DateCompleted><Year>2000</Year><Month>07</Month><Day>13</Day></DateCompleted><DateRevised><Year>2017</Year><Month>02</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0732-183X</ISSN><JournalIssue CitedMedium="Print"><Volume>18</Volume><Issue>4</Issue><PubDate><Year>2000</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</Title><ISOAbbreviation>J. Clin. Oncol.</ISOAbbreviation></Journal><ArticleTitle>Results of a randomized study of IM862 nasal solution in the treatment of AIDS-related Kaposi's sarcoma.</ArticleTitle><Pagination><MedlinePgn>716-23</MedlinePgn></Pagination><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Although advances have been made in the treatment of AIDS-related Kaposi's sarcoma (AIDS-KS) with systemic chemotherapy, less toxic therapies are needed. IM862 is a naturally occurring peptide with antiangiogenic properties and was thus studied in patients with AIDS-KS.</AbstractText><AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">IM862 was given as intranasal drops at a dose of 5 mg. Patients were randomized to two dosing schedules given in repeated cycles until disease progression or unacceptable toxicity: 5 days of therapy followed by 5 days off (n = 18) and every other day dosing (n = 26).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Forty-two male patients and two female patients with a median age of 38 years (range, 22 to 53 years) were accrued. Twenty-one patients (47%) had more than 50 mucocutaneous lesions, 14 (32%) had lymphedema, and none had visceral involvement. Thirty-three patients (75%) had received prior systemic chemotherapy. Twenty-four patients (55%) had CD4(+) lymphocyte count </AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">IM862 given as intranasal drops is well tolerated and has antitumor activity in patients with AIDS-KS. A randomized double-blinded study to define the activity of IM862 in patients with AIDS-KS is in progress.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tulpule</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Medicine, Division of Hematology, Kenneth Norris Cancer Hospital and Research Institute, University of Southern California School of Medicine, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scadden</LastName><ForeName>D T</ForeName><Initials>DT</Initials></Author><Author ValidYN="Y"><LastName>Espina</LastName><ForeName>B M</ForeName><Initials>BM</Initials></Author><Author ValidYN="Y"><LastName>Cabriales</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Howard</LastName><ForeName>W</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Shea</LastName><ForeName>K</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Gill</LastName><ForeName>P S</ForeName><Initials>PS</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Oncol</MedlineTA><NlmUniqueID>8309333</NlmUniqueID><ISSNLinking>0732-183X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020533">Angiogenesis Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004151">Dipeptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016228">Endothelial Growth Factors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017320">HIV Protease Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008222">Lymphokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020033">Protein Isoforms</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D042461">Vascular Endothelial Growth Factor A</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D042442">Vascular Endothelial Growth Factors</NameOfSubstance></Chemical><Chemical><RegistryNumber>122933-59-9</RegistryNumber><NameOfSubstance UI="C060736">thymogen</NameOfSubstance></Chemical><Chemical><RegistryNumber>38101-59-6</RegistryNumber><NameOfSubstance UI="C057081">alpha-glutamyltryptophan</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CitationSubset>X</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D017088" MajorTopicYN="N">AIDS-Related Opportunistic Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000281" MajorTopicYN="N">Administration, Intranasal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020533" MajorTopicYN="N">Angiogenesis Inhibitors</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018791" MajorTopicYN="N">CD4 Lymphocyte Count</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004151" MajorTopicYN="N">Dipeptides</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004334" MajorTopicYN="N">Drug Administration Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016228" MajorTopicYN="N">Endothelial Growth Factors</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists & inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005221" MajorTopicYN="N">Fatigue</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017320" MajorTopicYN="N">HIV Protease Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006261" MajorTopicYN="N">Headache</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008222" MajorTopicYN="N">Lymphokines</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists & inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009325" MajorTopicYN="N">Nausea</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010292" MajorTopicYN="N">Paresthesia</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020033" MajorTopicYN="N">Protein Isoforms</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists & inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012074" MajorTopicYN="N">Remission Induction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012514" MajorTopicYN="N">Sarcoma, Kaposi</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012878" MajorTopicYN="N">Skin Neoplasms</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D042461" MajorTopicYN="N">Vascular Endothelial Growth Factor A</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D042442" MajorTopicYN="N">Vascular Endothelial Growth Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>2</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>7</Month><Day>15</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>2</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10673512</ArticleId><ArticleId IdType="doi">10.1200/JCO.2000.18.4.716</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>États-Unis</li></country><region><li>Californie</li></region></list><tree><noCountry><name sortKey="Cabriales, S" sort="Cabriales, S" uniqKey="Cabriales S" first="S" last="Cabriales">S. Cabriales</name><name sortKey="Espina, B M" sort="Espina, B M" uniqKey="Espina B" first="B M" last="Espina">B M Espina</name><name sortKey="Gill, P S" sort="Gill, P S" uniqKey="Gill P" first="P S" last="Gill">P S Gill</name><name sortKey="Howard, W" sort="Howard, W" uniqKey="Howard W" first="W" last="Howard">W. Howard</name><name sortKey="Scadden, D T" sort="Scadden, D T" uniqKey="Scadden D" first="D T" last="Scadden">D T Scadden</name><name sortKey="Shea, K" sort="Shea, K" uniqKey="Shea K" first="K" last="Shea">K. Shea</name></noCountry><country name="États-Unis"><region name="Californie"><name sortKey="Tulpule, A" sort="Tulpule, A" uniqKey="Tulpule A" first="A" last="Tulpule">A. Tulpule</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000267 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 000267 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:10673512
|texte= Results of a randomized study of IM862 nasal solution in the treatment of AIDS-related Kaposi's sarcoma.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:10673512" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |